ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1251

Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1379

Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1206

Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1091

Serum Metabolomic Profiling Identifies Potential Biomarkers in Arthritis in the Elderly

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1274

Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1242

Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1058

Sex-Specific Associations Between Knee Synovial Fluid Biomarkers and Knee Osteoarthritis Pain

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1188

Sifting Through Complexity in a Methodological Manner: Identifying Key Items in Teaching Lupus to Medical Students Through Consensus

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1003

Significant Enrichment of Pathogenic CD206+CD163+ Macrophages in Rheumatoid Arthritis Synovial Tissue with Distinct Transcriptional Signatures

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1146

Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an Academic Hospital Setting

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

8:30AM-10:30AM: Abstract Number: 1293

Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1389

Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1069

Supporting Patient-Centered Care in the Pediatric Rheumatology Setting: Patient, Family and Provider Experiences with OurNotes

Health Services Research Poster II: Care Models and Innovation (1061–1082)

8:30AM-10:30AM: Abstract Number: 1382

Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1025

Survival of Patients with Idiopathic Inflammatory Myopathy in Slovenia

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].